Gross M D, Skinner R W, Grossman H B
Invest Radiol. 1984 Nov-Dec;19(6):530-4. doi: 10.1097/00004424-198411000-00011.
The results of an in vitro mixed hemadsorption (MHA) assay predicted the success of in vivo tumor localization using a radioiodinated, monoclonal, IgG1 antibody (A2) with reactivity to the human bladder carcinoma cell line RT4. In vitro, murine monoclonal antibodies A2 and G6, demonstrated reactivity to RT4 with titers of 1/1024 and 1/4 by MHA assay, respectively. In vivo results obtained with RT4 xenografts in athymic nude, Balb/c, mice indicated tumor uptakes of 1.10% dose/gram with A2 and 0.29% dose/gram with G6 at seven days after radiotracer injection. Successful scintigraphic imaging of tumor xenografts was achieved with A2 but not with G6 or radioiodinated mouse serum albumin.
体外混合血细胞吸附(MHA)试验结果预测,使用对人膀胱癌细胞系RT4有反应性的放射性碘化单克隆IgG1抗体(A2)进行体内肿瘤定位会取得成功。在体外,鼠单克隆抗体A2和G6通过MHA试验分别显示对RT4有反应性,效价分别为1/1024和1/4。在无胸腺裸鼠Balb/c中用RT4异种移植瘤获得的体内结果表明,在注射放射性示踪剂7天后,A2组肿瘤摄取量为1.10%剂量/克,G6组为0.29%剂量/克。用A2成功实现了肿瘤异种移植瘤的闪烁成像,而G6或放射性碘化小鼠血清白蛋白则未实现。